Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Amortization - Deferred Charges (2016 - 2021)

Zevra Therapeutics (ZVRA) has disclosed Amortization - Deferred Charges for 6 consecutive years, with $150000.0 as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Amortization - Deferred Charges fell 73.73% year-over-year to $150000.0, compared with a TTM value of $150000.0 through Dec 2021, down 93.49%, and an annual FY2021 reading of $150000.0, down 93.49% over the prior year.
  • Amortization - Deferred Charges was $150000.0 for Q1 2021 at Zevra Therapeutics, down from $582000.0 in the prior quarter.
  • Across five years, Amortization - Deferred Charges topped out at $675000.0 in Q4 2019 and bottomed at $150000.0 in Q1 2021.
  • Average Amortization - Deferred Charges over 4 years is $440692.3, with a median of $390000.0 recorded in 2018.
  • The sharpest move saw Amortization - Deferred Charges surged 88.2% in 2020, then crashed 73.73% in 2021.
  • Year by year, Amortization - Deferred Charges stood at $512000.0 in 2018, then soared by 31.84% to $675000.0 in 2019, then decreased by 13.78% to $582000.0 in 2020, then tumbled by 74.23% to $150000.0 in 2021.
  • Business Quant data shows Amortization - Deferred Charges for ZVRA at $150000.0 in Q1 2021, $582000.0 in Q4 2020, and $578000.0 in Q3 2020.